Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Pharma Cracking The U.S. Market Via Reverse Mergers Draw Attention From Authorities

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - A number of Chinese companies publicly traded in the U.S., including several in the pharmaceutical space, have come under the spotlight in the last 18 months after getting to market through reverse mergers

You may also be interested in...



Does Two Make A Trend? 3SBio Joins U.S.-listed Chinese Firms Going Private

On the heels of ShangPharma, 3SBio’s move highlights depressed valuation for Chinese companies. The large premium should seal the deal for the company with a growing pipeline and revenues, analysts say.

Will WuXi Benefit From Rival ShangPharma Going Private?

China’s second largest CRO ShangPharma is likely to go private after a proposal from its founder, and some say the exit may also help its larger rival WuXi PharmaTech.

Facing Potential Shareholder Suit And SEC Inquiry In U.S., China Sky One Medical Tries To Reassure Investors

BEIJING - While facing a potential shareholders' suit for possible violation of U.S. laws, the leadership of China Sky One Medical Inc. sought to reassure investors by disclosing a rise in earnings for 2010 and inviting investors to visit the firm's headquarters in Harbin, an ice-covered Chinese city that borders Russia's Siberia

Related Content

UsernamePublicRestriction

Register

SC078371

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel